Biotechnology

AI drug discovery firm Insilico Medicine soars in its Hong Kong debut, the city's largest biotech IPO of 2025, validating a new tech-driven era for medicine.

Dr. Lu Xianping, crowned EY Entrepreneur Of The Year, didn't just invent new drugs; he helped reinvent China's entire pharmaceutical industry.

As 10x Genomics preps for its J.P. Morgan spotlight, investors seek a clear path to profit amid fierce competition and groundbreaking innovation.

With CEO David Endicott set to present at the J.P. Morgan Healthcare Conference, all eyes are on Alcon's strategy for innovation and market growth.

Emmaus Life Sciences outsources its sickle cell drug Endari® in North America to focus on global growth, as NeoImmuneTech gains a key U.S. market foothold.

The biopharma investment giant has now acquired 100% of the royalty stream for Roche's blockbuster SMA drug, a strategic move years in the making.

As CooperCompanies heads to the J.P. Morgan conference, all eyes are on CEO Al White's strategic vision for its dual vision and women's health units.

With a novel therapy from newborn heart cells, Secretome Therapeutics heads to J.P. Morgan to showcase its progress against intractable heart failure.

Oncodesign Precision Medicine and Navigo Proteins end their radiotheranostics pact, shifting focus to internal programs amid high-stakes R&D challenges.

With promising survival data and a pivotal Phase 3 trial underway, Imunon's localized immunotherapy could finally change the game for ovarian cancer.

The Danish firm scraps its 2025 revenue forecast, accepting a larger loss in a bold move to secure more lucrative future deals for its key drug candidates.

Biotech pioneer Dr. Patrick Soon-Shiong is named a top influencer in oncology, boosting ImmunityBio amid strong sales and a promising drug pipeline.

Ultragenyx's stock plummets after its Osteogenesis Imperfecta drug fails to reduce fractures, a major blow for patients and a test of the firm's pipeline.

As its cash runway shortens, Longeveron's novel stem cell therapy gets a major boost with selection for a prestigious Alzheimer's health moonshot.

INOVIO's promising non-surgical treatment for a rare disease faces FDA scrutiny, casting doubt on its fast-track approval and impacting patient hopes.

Genmab discontinues its 'encouraging' lung cancer drug, acasunlimab, in a bold strategic pivot to accelerate its most promising late-stage assets.

Setrusumab, a promising drug for Osteogenesis Imperfecta, failed to reduce fractures in key trials, triggering a market collapse and strategic overhaul.

A pivotal trial for an acute myeloid leukemia drug is delayed for a promising reason: patients are surviving longer than anticipated, fueling cautious optimism.

With promising new drugs for obesity and liver disease, clinical-stage MetaVia steps into the spotlight at a key industry conference, facing giants and high hopes.

Azenta divests its medical refrigeration unit to streamline its portfolio, signaling a strategic pivot to its high-growth multiomics and sample management services.